3 Things You Need to Know
Standard of careIsn't working
You needIndividualized treatment
TimeIs of the essence
Nick: Patient Survivor
The day after his graduation from San Diego State University, Nick was diagnosed with a recurrence of his malignant meningioma. Nick knew he wasn’t going to have a lot of options, but we had just opened a Phase 0 clinical trial for this exact indication.
Tumors We Treat
As the Ivy Brain Tumor Center grows, every patient, regardless of diagnosis or stage of the brain tumor, will have the option to enroll in a Phase 0 clinical trial.
Common subtypes include astrocytoma, oligodendroglioma, glioblastoma, and gliosarcoma
Also known as ‘secondary’ brain tumors; originate from cancer in another part of the body
Primary brain tumors derived from the lining of the brain, known as the meninges
Arises from the ependymal cells that line the ventricles of the brain and the center of the spinal cord
Arises from small nests of cells near the pituitary stalk at the base of the skull, near the pituitary gland, third ventricle, and optic nerve
Occurs in the pineal region of the brain that may or may not involve the pineal gland
A COMMUNITY OF CAREGIVERS
Nurse who fought coronavirus in New York now battles his own brain cancer
Ian’s story has moved the country for his strength and selfless service on the COVID-19 frontlines in NYC. Now, facing a battle of his own, he’s turning to Dr. Nader Sanai and his team at the Ivy Brain Tumor Center and Barrow Neurological Institute to help him fight one of the most aggressive forms of brain cancer, glioblastoma.
Arizona is Leading the Charge in Battling one of the ‘Deadliest Diseases Known to Mankind’
Chamber Business News highlights the Ivy Brain Tumor Center’s resilience in fighting brain tumors despite the pandemic and the importance of Glioblastoma Awareness Day. Observed as a day to honor those who have been impacted by the disease, the initiative also supports efforts to develop better treatment options that will improve patients’ long-term prognosis.
Phoenix nurse inspires hope during battle with brain cancer
Dr. Nader Sanai, director of the Ivy Brain Tumor Center, says although the survival rate is low it doesn’t mean there isn’t hope to beat cancer. “These are populational statistics, they don’t describe you or predict your future.” He and Youngblood are teaming up to bring awareness to the disease for Glioblastoma Awareness Day. Sanai says a day focusing on brain cancer is important because it hasn’t seen the same progress in therapies like breast or prostate cancer.
Meghan McCain recognizes Ivy Brain Tumor Center
On May 27, 2020, Meghan McCain used her national platform to recognize Brain Tumor Awareness Month and her personal connection to this deadly disease on The View. She encourages people to support the Ivy Brain Tumor Center in our mission to cure brain cancer.
Phoenix nurse who helped fight New York’s COVID-19 surge now battling brain cancer
The Arizona Republic shares the story of Ian Youngblood, a 29-year-old nurse from Arizona who received a harrowing diagnosis of glioblastoma while helping fight COVID-19 on the frontlines in NYC. Dr. Nader Sanai weighs in on why these types of tumors are so hard to control and what it will take to move the needle on identifying new, effective treatment options.
Benjamin Cravatt, Ph.D. Joins Ivy Brain Tumor Center’s Scientific Advisory Board
The Ivy Brain Tumor Center at Barrow Neurological Institute has announced the appointment of Benjamin Cravatt, Ph.D to its Scientific Advisory Board. Dr. Cravatt is a world-renowned chemical biologist with extensive experience in drug discovery and drug development.
Ivy Foundation Makes Multi-million Dollar Contribution To AZ Coronavirus Relief Fund
“It’s very important to me that the medical personnel in this state have the right tools and supplies to fight this battle,” said Catherine Ivy, co-founder of the Ivy Brain Tumor Center.
3 Questions on Phase 0 Clinical Trials for Brain Tumors
The Ivy Brain Tumor Center at the Barrow Neurological Institute is a nonprofit center conducting early phase clinical trials of new therapeutics for brain tumors. In this interview with Oncology Times, Dr. Nader Sanai explains how the phase 0 trials work and why the center is so excited about them.